RVL Pharmaceuticals PLC expected to post a loss of 16 cents a share - Earnings Preview

RVL Pharmaceuticals

17/03/2023 13:20

* RVL Pharmaceuticals PLC  RVLP.OQ   RVLP.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 20. 
    * The Bridgewater New Jersey-based  company is expected to
report 
a 340.7% increase in revenue to $12.604 million from $2.86
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for RVL Pharmaceuticals
PLC
is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $3.3​, above​ its last closing price
of $1.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.15       -0.16      -0.16     Met     -0.5
 Jun. 30 2022  -0.20       -0.21      -0.14     Beat    32.5
 Mar. 31 2022  -0.16       -0.17      -0.25     Missed  -45.6​
 Dec. 31 2021  -0.25       -0.27      -0.30     Missed  -12.5
 ​​Sep.        -0.31       -0.31      -0.28     Beat    11.1
 30 2021                                                
 Jun. 30 2021  -0.14       -0.14      -0.28     Missed  -100​
 Mar. 31 2021  -0.23       -0.23      -0.15     Beat    36.2
 Dec. 31 2020  -0.28       -0.24      -0.88     Missed  -271.8
 This summary was machine generated March 17 at 13:20 GMT.  All
figures in US dollars  unless otherwise stated